AstraZeneca is the latest pharma company enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC.

AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, ...

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

Given that the Australian government heavily subsidizes pharmaceuticals— spending more than $AU16.7 billion annually through ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

AstraZeneca has returned to recent licensing partner CSPC Pharmaceuticals with $110 million in upfront cash to start work on ...

AstraZeneca said it entered into a strategic research collaboration with China's CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

Researchers from King's College London have called for urgent changes to the way new antibiotics are developed to address the ...